MYND Life Sciences Inc.
MYND.CN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.35M
Close$
$-0.06
190.7% downside
Current Fair Value
190.7% downsideOvervalued by 190.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.35 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.03 |
| Beta | 0.98 |
| Outstanding Shares | 46,274,624 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.18 |
|---|---|
| PEG | 7.64 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About MYND Life Sciences Inc.
0
CEO: Wilfred A. Jefferies MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the ...